The emerging role of eicosapentaenoic acid as an important psychoactive natural product: Some answers but a lot more questions

Lipid Insights

Volumn 2 1, Issue , 2008, Pages 89-97

  Ross, Brian M ^a  

^a LAKEHEAD UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859798711     PISSN: None     EISSN: 11786353     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Appleton, K.M., Peters, T.J., Hayward, R.C., Heatherley, S.V., McNaughton, S.A., Rogers, P.J., Gunnell, D., Ness, A.R. and Kessler, D. 2007. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc. Psychiatry Psychiatr. Epidemiol., 42:100-4.
2. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N., Petasis, N.A., Blumberg, R.S. and Serhan, C.N. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A., 102:7671-6.
3. Astorg, P., Couthouis, A., Bertrais, S., Arnault, N., Meneton, P., Guesnet, P., Alessandri, J.M., Galan, P. and Hercberg, S. 2008. Association of fi sh and long-chain n-3 polyunsaturated fatty acid intakes with the occurrence of depressive episodes in middle-aged French men and women. Prostaglandins Leukot Essent Fatty Acids, 78:171-82.
4. Babcock, T., Helton, W.S. and Espat, N.J. 2000. Eicosapentaenoic acid (EPA): an antiinfl ammatory omega-3 fat. Nutrition, 16:1116-8.
5. Balk, E.M., Lichtenstein, A.H., Chung, M., Kupelnick, B., Chew, P. and Lau, J. 2006. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis, 189:19-30.
6. Bays, H.E., Tighe, A.P., Sadovsky, R. and Davidson, M.H. 2008. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther., 6:391-409.
7. Beavers, K.M., Beavers, D.P., Bowden, R.G., Wilson, R.L. and Gentile, M. 2008. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton), 13:284-8.
8. Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P. and Clarke, W.P. 1998. Effector pathway-dependent relative effi cacy at serotonin type 2A and 2C receptors: evidence for agonist-directed traffi cking of receptor stimulus. Mol. Pharmacol., 54:94-104.
9. Berge, R.K., Masen, L., Vaagenes, H., Tronstad, K.J., Gottlicher, M. and Rustan, A.C. 1999. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem. J., 343:191-7.
10. Berquin, I.M., Edwards, I.J. and Chen, Y.Q. 2008. Cancer Lett. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett., 269:363-77.
11. Blondeau, N., Pétrault, O., Manta, S., Giordanengo, V., Gounon, P., Bordet, R., Lazdunski, M. and Heurteaux, C. 2007. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ. Res., 101:176-84.
12. Bosetti, F., Rintala, J., Seemann, R., Rosenberger, T.A., Contreras, M.A., Rapoport, S.I. and Chang, M.C. 2002. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry, 7:845-50.
13. Brietzke, E. and Kapczinski, F. 2008. TNF-alpha as a molecular target in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32:1355-61.
14. Buydens-Branchey, L., Branchey, M. and Hibbeln, J.R. 2008. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32:568-75.
15. Calviello, G., Serini, S. and Piccioni, E. 2007. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr. Med. Chem., 14:3059-69.
16. Castrén, E. and Rantamäki, T. 2008. Neurotrophins in depression and antidepressant effects. Novartis Found Symp., 289:43-52.
17. Conklin, S.M., Gianaros, P.J., Brown, S.M., Yao, J.K., Hariri, A.R., Manuck, S.B. and Muldoon, M.F. 2007. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci. Lett., 421:209-12.
18. Curtis-Prior, P. 2004. The Eicosanoids London, U.K: Wiley. Davis, J.D. and Tremont, G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva. Endocrinol., 32:49-65.
19. Diaz, O., Berquand, A., Dubois, M., Di Agostino, S., Sette, C., Bourgoin, S., Lagarde, M., Nemoz, G. and Prigent, A.F. 2002. The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. J. Biol. Chem., 277:39368-7.
20. Doolan, G.K., Panchal, R.G., Fonnes, E.L., Clarke, A.L., Williams, D.A. and Petrou, S. 2002. Fatty acid augmentation of the cardiac slowly activating delayed rectifi er current (IKs) is conferred by hminK. FASEB J., 16:1662-4.
21. du Bois, T.M., Deng, C., Bell, W. and Huang, X.F. 2006. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience, 139:1397-403.
22. Dyall, S.C., Michael, G.J., Whelpton, R., Scott, A.G. and Michael-Titus, A.T. 2007. Dietary enrichment with omega-3 polyunsaturated fatty acids reverses age-related decreases in the GluR2 and NR2B. glutamate receptor subunits in rat forebrain. Neurobiol. Aging, 28:424-39.
23. Emken, E.A., Adlof, R.O. and Gulley, R.M. 1994. Dietary linoleic acid infl uences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta., 1213:277-88.
24. Estes, K.C., Rose, B.T., Speck, J.J., Nutter, M.L. and Reitz, R.C. 1997. Effects of omega 3 fatty acids on receptor tyrosine kinase and PLC activities in EMT6 cells. J. Lipid Mediat. Cell Signal, 17:81-96.
25. Evans, K.L., Cropper, J.D., Berg, K.A. and Clarke, W.P. 2001. Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. J. Pharmacol. Exp. Ther., 297:1025-35.
26. Frangou, S., Lewis, M. and McCrone, P. 2006. Efficacy of ethyleicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry, 188:46-50.
27. Freeman, M.P., Hibbeln, J.R., Wisner, K.L., Davis, J.M., Mischoulon, D., Peet, M., Keck, P.E. Jr, Marangell, L.B., Richardson, A.J., Lake, J. and Stoll, A.L. 2006. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry, 67:1954-67.
28. Frodl, T., Möller, H.J. and Meisenzahl, E. 2008. Neuroimaging genetics: new perspectives in research on major depression? Acta. Psychiatr Scand, in press.
29. Ghelardoni, S., Tomita, Y.A., Bell, J.M., Rapoport, S.I. and Bosetti, F. 2004. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry, 56:248-54.
30. Guizy, M., Arias, C., David, M., Gonzalez, T. and Valenzuela, C. 2005. ω-3 and ω-6 polyunsaturated fatty acids block HERG channels. Am. J. Physiol. Cell Physiol., 289:C1251-60
31. Healy, D.A., Wallace, F.A., Miles, E.A., Calder, P.C. and Newsholm, P. 2000. Effect of moderate amounts of dietary fi sh oil on neutrophil lipid composition and function. Lipids, 35:763-8.
32. Honoré, E., Barhanin, J., Attali, B., Lesage, F. and Lazdunski, M. 1994. External blockade of the major cardiac delayed-rectifi er K? channel (Kv1.5) by polyunsaturated fatty acids. Proc. Natl. Acad. Sci. U.S.A., 91:1937-41.
33. Horrobin, D.F., Jenkins, K., Bennett, C.N. and Christie, W.W. 2002. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids, 66:83-90.
34. Huffman, J.C. and Stern, T.A. 2007. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin. Neurosci., 9:29-45.
35. Jazayeri, S., Tehrani-Doost, M., Keshavarz, S.A., Hosseini, M., Djazayery, A., Amini, H., Jalali, M. and Peet, M. 2008. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fl uoxetine, separately and in combination, in major depressive disorder. Aust. N. Z. J. Psychiatry, 42:192-8.
36. Johnson, M., Ostlund, S., Fransson, G., Kadesjö, B. and Gillberg, C. Omega-3/Omega-6 Fatty Acids for Attention Defi cit Hyperactivity Disorder: A Randomized Placebo-Controlled Trial in Children and Adolescents. J. Atten. Disord, in press.
37. Jude, S., Bedut, S., Roger, S., Pinault, M., Champeroux, P., White, E. and Le Guennec, J.Y. 2003. Peroxidation of docosahexaenoic acid is responsible for its effects on I TO and I SS in rat ventricular myocytes. Br. J. Pharmacol., 139:816-22.
38. Kanner, A.M. 2004. Structural MRI changes of the brain in depression. Clin. EEG Neurosci., 35:46-52.
39. Keck, P.E., Mintz, J., McElroy, S.L., Freeman, M.P., Suppes, T., Frye, M.A., Altshuler, L.L., Kupka, R., Nolen, W.A., Leverich, G.S., Denicoff, K.D., Gunze, H., Duan, N. and Post, R.M. 2006. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapenanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry, 60:1020-2.
40. Kim, J.M., Stewart, R., Kim, S.W., Yang, S.J., Shin, I.S. and Yoon, J.S. 2008. Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression. Br. J. Psychiatry, 192:268-74.
41. Kuperstein, F., Eilam, R. and Yavin, E. 2008. Altered expression of key dopaminergic regulatory proteins in the postnatal brain following perinatal n-3 fatty acid dietary deficiency. J. Neurochem., 106:662-71.
42. Leaf, A. 2001. The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain. Lipids, 36 (Suppl):S107-10.
43. Lee, H.J., Rao, J.S., Ertley, R.N., Chang, L., Rapoport, S.I. and Bazinet, R.P. 2007. Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl), 190:103-15.
44. Lee, J.H., O'Keefe, J.H., Lavie, C.J., Marchioli, R. and Harris, W.S. 2008. Omega-3 fatty acids for cardioprotection. Mayo Clin. Proc., 83:324-32.
45. Lehto, S.M., Hintikka, J., Niskanen, L., Tolmunen, T., Koivumaa-Honkanen, H., Honkalampi, K. and Viinamäki, H. 2008. Low HDL cholesterol associates with major depression in a sample with a 7-year history of depressive symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32:1557-61.
46. Lewis, A., Lookinland, S., Beckstrand, R.L. and Tiedeman, M.E. 2004. Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J. Am. Acad. Nurse Pract., 16:384-95.
47. Lin, P.Y. and Su, K.P. 2007. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant effi cacy of omega-3 fatty acids. J. Clin. Psychiatry, 68:1056-61.
48. Maes, M. 2008. The cytokine hypothesis of depression: infl ammation, oxidative and nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro. Endocrinol. Lett., 29:287-91.
49. Marangell, L.B., Martinez, J.M., Zboyan, H.A., Kertz, B., Kim, H.F. and Puryear, L.J. 2003. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. J. Psychiatry, 160:996-8.
50. Matta, J.A., Miyares, R.L. and Ahern, G.P. 2007. TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J. Physiol., 578:397-411.
51. McNamara, R.K., Hahn, C.G., Jandacek, R., Rider, T., Tso, P., Stanford, K.E. and Richtand, N.M. 2007. Selective defi cits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry, 62:17-24.
52. McNamara, R.K., Jandacek, R., Rider, T., Tso, P., Stanford, K.E., Hahn, C.G. and Richtand, N. M. 2008. Defi cits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res., 160:285-99.
53. McNamara, R.K., Ostrander, M., Abplanalp, W., Richtand, N.M., Benoit, S.C. and Clegg, D.J. 2006. Modulation of phosphoinositideprotein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids, 75:237-57.
54. Morcos, N.C. and Camilo, K. 2001. Acute and chronic toxicity study of fi sh oil and garlic combination. Int. J. Vitam. Nutr. Res., 71:306-12.
55. Murakami, K., Mizoue, T., Sasaki, S., Ohta, M., Sato, M., Matsushita, Y. and Mishima, N. 2008. Dietary intake of folate, other B. vitamins, and omega-3 polyunsaturated fatty acids in relation to depressive symptoms in Japanese adults. Nutrition, 24:140-7.
56. Nemets, B., Stahl, Z. and Belmaker, R.H. 2002. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry, 159:477-9.
57. Nemets, H., Nemets, B., Apter, A., Bracha, Z. and Belmaker, R.H. 2006. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am. J. Psychiatry, 163:1098-100.
58. Obajimi, O., Black, K.D., MacDonald, D.J., Boyle, R.M., Glen, I. and Ross, B.M. 2005. Differential effects of eicosapentaenoic and docosahexaenoic acids upon oxidant-stimulated release and uptake of arachidonic acid in human lymphoma U937 cells. Pharmacol. Res., 52:183-91.
59. Peet, M. and Horrobin, D.F. 2002. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen Psychiatry, 59:913-9.
60. Philbrick, D-J., Mahadevappa, V.G., Ackman, R.G. and Holub, B.J. 1987. Ingestion of fi sh oil or a derived n-3 fatty acid concentrate containing aicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. J. Nutr., 117:1663-70.
61. Piolot, A., Blache, D., Boulet, L., Fortin, L.J., Dubreuil, D., Marcoux, C., Davignon, J. and Lussier-Cacan, S. 2003. Effect of fi sh oil on LDL oxidation and plasma homocysteine concentrations in health. J. Lab Clin. Med., 141:41-9.
62. Piomelli, D., Pilon, C., Giros, B., Sokoloff, P., Martres, M.P. and Schwartz, J.C. 1991. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature, 353:164-7.
63. Puri, B.K., Richardson, A.J., Horrobin, D.F., Easton, T., Oatridge, A., Hajnal, J.V. and Bydder G.M. 2000. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int. J. Clin. Pract., 54:57-63.
64. Qu, Y., Chang, L., Klaff, J., Seemann, R. and Rapoport, S.I. 2003. Imaging brain phospholipase A2-mediated signal transduction in response to acute fl uoxetine administration in unanesthetized rats. Neuropsychopharmacology, 28:1219-26.
65. Rao, J.S., Ertley, R.N., Lee, H.J., DeMar, J.C. Jr., Arnold, J.T., Rapoport, S.I. and Bazinet, R.P. 2007. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry, 12:36-46.
66. Rapoport, S.I. and Bosetti, F. 2002. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry, 59:592-6.
67. Richardson, A.J. and Montgomery, P. 2005. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics, 115:1360-6.
68. Richardson, A.J. and Puri, B.K. 2002. A randomized double-blind, placebocontrolled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specifi c learning diffi culties. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26:233-9.
69. Richardson, A.J. 2008. n-3 Fatty acids and mood: the devil is in the detail. Br. J. Nutr., 99:421-31.
70. Ringbom, T., Huss, U., Stenholm, A., Flock, S., Skattebol, L., Perera, P. and Bohlin, L. 2001. COX-2 inhibitory effects of naturally occurring and modifi ed fatty acids. J. Nat. Prod., 64:745-9.
71. Rogers, P.J., Appleton, K.M., Kessler, D., Peters, T.J., Gunnell, D., Hayward, R.C., Heatherley, S.V., Christian, L.M., McNaughton, S.A. and Ness, A.R. 2008. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br. J. Nutr., 99:421-31.
72. Ross, B.M., Senguin, J. and Sieswerda, L. 2007. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids in Health and Disease, 6:21.
73. Ross, B.M. 2007. Omega-3 fatty acid defi ciency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med. Hypotheses, 68:515-24.
74. Sampath, H. and Ntambi, J.M. 2004. Polyunsaturated fatty acid regulation of gene expression. Nutr. Rev., 62:333-9.
75. Sampath, H. and Ntambi, J.M. 2005. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Ann. Rev. Nutr., 25:317-40.
76. Sanchez-Villegas, A., Henríquez, P., Figueiras, A., Ortuño, F., Lahortiga, F. and Martínez-González, M.A. 2007. Long chain omega-3 fatty acids intake, fi sh consumption and mental disorders in the SUN. cohort study. Eur. J. Nutr., 46:337-46.
77. Sergeeva, M., Strokin, M. and Reiser, G. 2005. Regulation of intracellular calcium levels by polyunsaturated fatty acids, arachidonic acid and docosahexaenoic acid, in astrocytes: possible involvement of phospholipase A2. Reprod. Nutr. Dev., 45:633-46.
78. Serhan, C.N., Yacoubian, S. and Yang, R. 2008. Anti-infl ammatory and proresolving lipid mediators. Annu Rev. Pathol., 3:279-312.
79. Siddiqui, R.A., Shaikh, S.R., Sech, L.A., Yount, H.R., Stillwell, W. and Zaloga, G.P. 2004. Omega 3-fatty acids: health benefi ts and cellular mechanisms of action. Mini Rev. Med. Chem., 4:859-71.
80. Silvers, K.M., Woolley, C.C., Hamilton, F.C., Watts, P.M. and Watson, R.A. 2005. Randomised double-blind placebo-controlled trial of fi sh oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids, 72:211-8.
81. Smith, W.L. 2005. Cyclooxygenases, peroxide tone and the allure of fi sh oil. Curr. Opin. Cell Biol., 17:174-82.
82. Song, C., Li, X., Kang, Z. and Kadotomi, Y. 2007. Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology, 32:736-44.
83. Stahl, S.M. 2000. Essential psychopharm acology. Neuroscientifi c basis and practical applications. 2nd edition. Cambridge, U.K: Cambridge University Press.
84. Stoll, A.L., Severus, W.E., Freeman, M.P., Rueter, S., Zboyan, H.A., Diamond, E., Cress, K.K. and Marangell, L.B. 1999. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebocontrolled trial. Arch. Gen. Psychiatry, 56:407-12.
85. Su, K.P., Huang, S.Y., Chiu, C.C. and Shen, W.W. 2003. Omega-3 fatty acids in major depressive disorder. A preliminary doubleblind, placebo-controlled trial. Eur. Neuropsychopharmacol., 13:267-71.
86. Umhau, J.C., Dauphinais, K.M., Patel, S.H., Nahrwold, D.A., Hebblin, J.R. and George, D.T. 2006. The relationship between folate and docosahexaenoic acid in men. Eur. J. Clin. Nutr., 60:352-7.
87. Vial, D. and Piomelli, D. 1995. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonicspecifi c phospholipase A2. J. Neurochem., 64:2765-72.
88. Wu, A., Ying, Z. and Gomez-Pinilla, F. 2004. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma., 21:1457-67.
89. Xiao, Y.F., Gomez, A.M., Morgan, J.P., Lederer, W.J. and Leaf, A. 1997. Suppression of voltage-gated L-type Ca2? currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc. Natl. Acad. Sci. U.S.A., 94:4182-7.
90. Yamashita, A., Sugiura, T. and Waku, K. 1997. Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. J. Biochem. (Tokyo), 122:1-16.
91. Yehuda, S., Rabinovitz, S. and Mostofsky, D.I. 2005. Mixture of essential fatty acids lowers test anxiety. Nutr. Neurosci., 8:265-7.